Journal Information
Share
Share
Download PDF
More article options
Visits
5
Letter - Research
Full text access
Available online 20 January 2025
Sebaceous carcinoma: clinical and demographic profile of patients in a tertiary referral hospital in Brazil
Visits
5
Tatiana Mina Yendoa,1, Flavia Mascarenhas Damiania,1, Suzana Matayoshib,1, Marcello Menta Simonsen Nicoa,
,1
a Department of Dermatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
b Department of Ophthalmology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
This item has received
Received 17 April 2024. Accepted 29 June 2024
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (1)
Table 1. Clinical characteristics of patients diagnosed with sebaceous carcinoma.
Full Text
Dear Editor,

Sebaceous carcinoma (SC) is a rare malignant neoplasm, described by Allaire in 1891, usually located in the head and neck and with a predilection for the periocular region (38.7%).1 It has a higher incidence in the elderly (6th to 7th decades of life), in males (58% of cases), and in Caucasian population (86.2%).1,2 The authors retrospectively evaluated 22 cases of patients diagnosed with at least one SC, including three patients diagnosed with two primary SC, between January 2006 and December 2020, in a Brazilian university hospital. As described in previous studies,2 males had a higher incidence of SC, corresponding to 55% of the evaluated cases. The mean age at diagnosis was 67 years (24 to 94 years of age) and the majority of patients were Caucasian.

Clinically, the diagnosed SC showed varied characteristics, presenting as papules, plaques, nodules or tumors, generally yellowish or erythematous, with telangiectasias, a pearly gloss, keratosis or ulceration. The craniocephalic and cervical regions were preferentially affected, and, in ten cases, the SC was located in the periocular region (six in the upper eyelid and four in the lower eyelid; Fig. 1A). One case of SC was described in the neck, one in the ear pinna (Fig. 1B), three in the malar region, five in the nasal region, one in the scalp, one in the lip (Fig. 1C) and one in the chin. Only two SC were diagnosed outside the head and neck area (shoulder and chest). Nine patients were investigated for the presence of Muir-Torre Syndrome (MTS), and only four had the loss of expression of at least one mismatch repair gene confirmed by immunohistochemistry. Half of the studied cases had a diagnosis of other skin tumors such as basal cell carcinomas (BCC), squamous cell carcinomas (SCC), sebaceous adenomas and sebaceomas, single or multiple, with or without association with MTS. Moreover, eight cases had a diagnosis of non-skin neoplasms such as (1) invasive ductal breast carcinoma (without association with MTS), (2) Hodgkin's lymphoma, (3) non-Hodgkin's lymphoma and colon adenocarcinoma, (4) bilateral retinoblastoma (not investigated for MTS), (5) colon adenocarcinoma, (6) sigmoid neuroendocrine tumor and hepatocarcinoma, (7) colon adenocarcinoma, duodenal papilla adenocarcinoma with liver metastasis and prostate adenocarcinoma, (8) colon adenocarcinoma and multiple myeloma (confirmed for MTS).

Fig. 1.

Clinical photographs of sebaceous carcinomas. (A) Sebaceous carcinoma in the lower eyelid. (B) Sebaceous carcinoma in the ear pinna. (C) Sebaceous carcinoma in the upper lip of a patient with MTS.

(0.92MB).

The treatment of choice in ten cases of SC was wide excision of the tumor. Mohs micrographic surgery was performed in one case, and in another case, radiotherapy was adopted as an adjuvant method. Only one case was treated with palliative radiotherapy. Four tumors were removed by shaving or saucerization. Patients mean follow-up time was four years, and only nine remained in outpatient follow-up until the end of the study. Three patients had SC metastasis: (1) one SC diagnosed in the lower eyelid, showed metastasis in a cervical lymph node, and wide excision was performed, without new recurrences; (2) two SC diagnosed in the upper and lower eyelids, with parotid and pulmonary metastases, were treated with excision of all tumors associated with radiotherapy, without recurrence; (3) one SC diagnosed in the shoulder, initially treated with wide excision, showed local recurrence one year later associated with lymph node metastasis, and died. There were also two deaths from causes unrelated to SC (hepatocarcinoma and multiple myeloma). The collected data are shown in Table 1.

Table 1.

Clinical characteristics of patients diagnosed with sebaceous carcinoma.

Case N.  Gender  Age  Location  Tumor characteristics  Other skin tumors  Personal history  Muir-Torre Syndrome  Metastasis  Treatment  Recurrence  Follow-up (time in years) 
51  Neck and lip  Erythematous papule and ulcerated yellowish papule  32 sebaceous adenomas and 1 sebaceoma  Colon adenocarcinoma  Confirmed: loss of MLH1 and PMS2 expression  Absent  Shaving  Absent  Outpatient follow-up (6) 
94  Malar region  No description  2 BCC  NN  Absent  No description  Wide local excision  No description  Lost to follow-up (2) 
64  Nose  No description  11 SCC, 7 BCC and 1 malignant sweat gland tumor  NN  Not investigated  Absent  No description  Absent  Outpatient follow-up (14) 
79  Malar  Pearly keratotic papule  3 BCC  NN  Not investigated  No description  Wide local excision  No description  Lost to follow-up (<1) 
60  Nose  Ulcerated erythematous plaque  1 BCC  Sigmoid neuroendocrine tumor and hepatocellular carcinoma  Confirmed: loss of MSH-2 and MSH-6 expression  Absent  Shaving  Absent  Death from hepatocarcinoma (2) 
67  Scalp  Pearly erythematous tumor with telangiectasia  1 SCC  NN  Absent  No description  Wide local excision  No description  Lost to follow-up (<1) 
61  Lower eyelid  Yellowish nodule with telangiectasias and ulceration  Absent  NN  Not investigated  Cervical lymph node  Wide local excision  Absent  Outpatient follow-up (5) 
81  Upper eyelid  Reddish nodule with telangiectasias  Absent  NN  Not investigated  No description  Local excision  No description  Lost to follow-up (1) 
65  Nose  No description  2 sebaceous adenomas and 1 SCC  Non-Hodgkin lymphoma and colon adenocarcinoma  Not investigated  No description  No description  No description  Lost to follow-up (<1) 
10  69  Shoulder  Erythematous nodule with pearly gloss  1 BCC  NN  Not investigated  Lymph node  Wide local excision  Local recurrence after one year with lymph node involvement  Death (2) 
11  86  Malar region  Keratotic plaque  2 SCC  NN  Not investigated  No description  Saucerization  No description  Lost to follow-up (<1) 
12  64  Upper eyelid  No description  Absent  NN  Absent  Absent  Wide local excision  Absent  Outpatient follow-up (4) 
13  71  Chest  Erythematous and grayish tumor  2 SCC  NN  Not investigated  Absent  Wide local excision  Absent  Outpatient follow-up (2) 
14  67  Nose  Exophytic ulcerated nodule  Absent  Colon adenocarcinoma, duodenal papilla adenocarcinoma with liver metastasis and prostate adenocarcinoma  Confirmed: loss of MSH-2 and MSH-6 expression  Absent  Saucerization  Absent  Outpatient follow-up (<1) 
15  24  Upper eyelid  No description  Absent  Bilateral retinoblastoma  Not investigated  No description  Local excision  No description  Lost to follow-up (<1) 
16  52  Chin  Exophytic plaque  1 BCC, 1 sebaceoma and 2 sebaceous adenomas  Colon adenocarcinoma and multiple myeloma  Confirmed: loss of MSH-2 expression  No description  Wide local excision  Absent  Death from multiple myeloma (1) 
17  74  Nose  Yellowish exophytic nodule with telangiectasias and ulceration  Absent  Hodgkin's lymphoma  Not investigated  No description  No description  No description  Lost to follow-up (<1) 
18  82  Ear pinna  Keratotic nodule  Absent  Invasive ductal breast carcinoma  Absent  Absent  Mohs micrographic surgery  Absent  Outpatient follow-up (1) 
19  62  Upper eyelid  No description  Absent  NN  Not investigated  No description  Unknown  Unknown  Lost to follow-up (<1) 
20  71  Upper and lower eyelids  Yellowish ulcerated nodule  Absent  NN  Absent  Absent  Local excision and adjuvant RT  Absent  Outpatient follow-up (1) 
21  43  Upper and lower eyelids  No description  Absent  NN  Not investigated  Parotid gland and lung  Excision of the primary tumor, parotid gland and lung metastases and RT  Absent  Outpatient follow-up (14) 
22  93  Lower eyelid  Ulcerated plaque  Absent  NN  Not investigated  No description  Palliative RT  Unknown  Lost to follow-up (3) 

BCC, Basal Cell Carcinoma; SCC, Squamous Cell Carcinoma; F, Female; M, Male; NN, Nothing Noteworthy; RT, Radiotherapy.

Morphologically, SC can present with varied characteristics, mimicking benign tumors (sebaceous hyperplasias, sebaceous adenomas, sebaceomas, nevocellular nevi), malignant neoplasms (BCC and SCC), as well as inflammatory diseases, such as chalazion, blepharitis and keratitis. The latter conditions are considered differential diagnoses of periocular lesions.1,3 SC diagnosis is confirmed by histopathology of biopsies representing the deep dermis (Fig. 2) and immunohistochemical examination (positive EMA (epithelial membrane antigen) positive oil red O stain, positive Sudan black, with these last two stains performed on frozen sections; Fig. 3). Histopathology of SC is characterized by the presence of irregular and asymmetric sebaceous lobules; sebocytes present a vacuolated cytoplasm, hyperchromasia and nuclear atypia (Fig. 2).2,4 Because it is rare and mimics other dermatoses, inadequate diagnostic procedures, such as shaving and saucerization, are performed, causing a further delay in the diagnosis of SC.

Fig. 2.

(A) Histopathology of sebaceous carcinoma in the left mandibular region (Hematoxylin & eosin, 10x). (B) Histological examination revealed the presence of disordered invasion of the dermis by ill-defined lobules of atypical sebocytes (Hematoxylin & eosin, ×100). (C) In a higher power view, atypical sebocytes can be observed in this tumor (Hematoxylin & eosin, ×400).

(0.96MB).

Most cases of SC occur sporadically and have as risk factors immunosuppression, especially solid organ transplantation and acquired immunodeficiency syndrome, exposure to ultraviolet (UV) radiation, radiotherapy, viral infections, a history of familial retinoblastoma and MTS.5 The predominance of SC lesions in photoexposed areas was documented in the present study, with 90% of the tumors located in the head and neck and 40% in the eyelid region (among them, two cases with lesions in the upper and lower eyelids). Another piece of evidence that the patients in the present sample had significant photodamage is the diagnosis of other UV-induced skin tumors, such as BCC and SCC, observed in 45% of the cases. Brazil is a country with a high incidence of UV radiation due to its geographic location, thus increasing the risk of the population for developing UV-induced skin malignant tumors.

MTS is a rare autosomal dominant disease in which there is a mutation in a DNA mismatch repair gene (MLH-1, MSH-2, MSH-6, PMS1 Homolog 2 and PMS-2),4,6,7 characterized by the presence of benign or malignant neoplasms originating in sebaceous glands that may or may not occur concomitantly with other malignant neoplasms, especially of the gastrointestinal tract and genitourinary system, the most common being colorectal cancer (80% of cases). Keratoacanthoma and BCC with sebaceous differentiation are also commonly diagnosed in these patients.6 In this disease, SC occurs at earlier age ranges and is common in extraocular regions.8 Suspicion of MTS based on the diagnosis of sebaceous tumors allows the early screening for visceral malignancies, which may favor a better prognosis for patients with this syndrome. In the present series, four cases were diagnosed with MTS, showing loss of expression of at least one DNA mismatch repair gene (Fig. 3) and with a history of colon neoplasia accompanied or not by another primary neoplasia. Only one case of MTS did not have another cutaneous neoplasia.

Fig. 3.

Immunohistochemical examination of a skin biopsy of sebaceous carcinoma from the left mandibular region of a patient with MTS. Immunohistochemical examination demonstrated the expression of mismatch repair genes (A) MLH-1 present (×40), (B) loss of MSH-2 (×400), (C) loss of MSH-6 (x40) and (D) loss of PMS-2 (x400).

(1.45MB).

Surgical treatment with tumor excision and intraoperative margin assessment is the most indicated for SC.2,9 However, in periocular tumors, this can be challenging. In cases of margin involvement or locally advanced tumor with narrow margins, adjuvant radiotherapy may be indicated.2,10 In the present series, there is a report of only one case treated with Mohs micrographic surgery (SC of the ear pinna) and one of adjuvant radiotherapy (SC of the upper and lower eyelids). Both patients were maintained on outpatient follow-up without recurrence of the primary tumor or metastases. The limited availability of trained professionals and equipment to perform Mohs micrographic surgery limits its use.

SC is an aggressive malignant tumor with high mortality (5%‒10%) and recurrence (16%‒18%) rates.3 Poor prognosis factors include tumors larger than 2 cm, multicentric disease, poorly differentiated lesions, and simultaneous involvement of the upper and lower eyelids.9 Three cases of metastases, one case of recurrence, and one death were observed in the present series, but these data were not sufficient to determine the metastasis, recurrence, and mortality rates, since among the limitations of the present study, the loss of patients to follow-up and incomplete documentation made it impossible to calculate them.

This retrospective case series discusses the importance of considering SC as a differential diagnosis, especially in periocular lesions. Early diagnosis, investigation of risk factors, and MTS are important to adopt the appropriate management for the benefit of the patient.

Authors' contributions

Tatiana Mina Yendo: Design and planning of the study; collection, analysis and interpretation of data; drafting and editing of the manuscript, collection, analysis and interpretation of data; critical review of the literature; approval of the final version of the manuscript.

Flavia Mascarenhas Damiani: Collection, analysis and interpretation of data; statistical analysis; drafting and editing of the manuscript; collection, analysis and interpretation of data; critical review of the literature; approval of the final version of the manuscript.

Suzana Matayoshi: Critical review of important intellectual content; approval of the final version of the manuscript.

Marcello Menta Simonsen Nico: Design and planning of the study; critical review of important intellectual content; effective participation in research orientation; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; approval of the final version of the manuscript.

Financial support

None declared.

Conflicts of interest

None declared.

Acknowledgement

The authors would like to thank Dr. Neusa Yuriko Sakai Valente, from the Department of Dermatology at the Faculty of Medicine, Universidade de São Paulo, for assisting in the anatomopathological and immunohistochemical evaluations for this investigation.

References
[1]
T. Dasgupta, L.D. Wilson, J.B. Yu.
A retrospective review of 1349 cases of sebaceous carcinoma.
Cancer, 115 (2009), pp. 158-165
[2]
J.L. Owen, N. Kibbi, B. Worley, R.C. Kelm, J.V. Wang, C.A. Barker, et al.
Sebaceous carcinoma: evidence-based clinical practice guidelines.
Lancet Oncol, 20 (2019), pp. e699-e714
[3]
C.K. Orr, F. Yazdanie, R. Shinder.
Current review of sebaceous cell carcinoma.
Curr Opin Ophthalmol, 29 (2018), pp. 445-450
[4]
M.V. Cicinelli, S. Kaliki.
Ocular sebaceous gland carcinoma: an update of the literature.
Int Ophthalmol, 39 (2019), pp. 1187-1197
[5]
A. Wu, S.N. Rajak, S.C. Huilgol, C. James, D. Selva.
Cutaneous sebaceous carcinoma.
Australas J Dermatol, 61 (2020), pp. e283-e292
[6]
M.R. Sargen, G.J. Starrett, E.A. Engels, E.K. Cahoon, M.A. Tucker, A.M. Goldstein.
Sebaceous carcinoma epidemiology and genetics: emerging concepts and clinical implications for screening, prevention, and treatment.
Clin Cancer Res, 27 (2021), pp. 389-393
[7]
P.R. Cohen, R. Kurzrock.
Germline testing of mismatch repair genes is needed in the initial evaluation of patients with Muir-Torre Syndrome-associated cutaneous sebaceous neoplasms: a case series.
Cureus, 15 (2023),
[8]
A.M. John, R.A. Schwartz.
Muir-Torre syndrome (MTS): an update and approach to diagnosis and management.
J Am Acad Dermatol, 74 (2016), pp. 558-566
[9]
N. Kibbi, B. Worley, J.L. Owen, R.C. Kelm, C.K. Bichakjian, S. Chandra, et al.
Sebaceous carcinoma: controversies and their evidence for clinical practice.
Arch Dermatol Res, 312 (2020), pp. 25-31
[10]
C. Prieto-Granada, P. Rodriguez-Waitkus.
Sebaceous carcinoma of the eyelid.
Cancer Control, 23 (2016), pp. 126-132

Study conducted at the Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

ORCID IDs: Tatiana Mina Yendo: 0000-0002-0067-8933, Flavia Mascarenhas Damiani: 0000-0002-2736-3181, Suzana Matayoshi: 0000-0003-0630-4091, Marcello Menta Simonsen Nico: 0000-0001-7968-0624.

Copyright © 2024. Sociedade Brasileira de Dermatologia
Download PDF
Idiomas
Anais Brasileiros de Dermatologia
Article options
Tools
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.